key: cord-0757743-00leff27
authors: Manry, Jeremy; Bastard, Paul; Gervais, Adrian; Le Voyer, Tom; Rosain, Jérémie; Philippot, Quentin; Michailidis, Eleftherios; Hoffmann, Hans-Heinrich; Eto, Shohei; Garcia-Prat, Marina; Bizien, Lucy; Parra-Martínez, Alba; Yang, Rui; Haljasmägi, Liis; Migaud, Mélanie; Särekannu, Karita; Maslovskaja, Julia; de Prost, Nicolas; Tandjaoui-Lambiotte, Yacine; Luyt, Charles-Edouard; Amador-Borrero, Blanca; Gaudet, Alexandre; Poissy, Julien; Morel, Pascal; Richard, Pascale; Cognasse, Fabrice; Troya, Jesus; Trouillet-Assant, Sophie; Belot, Alexandre; Saker, Kahina; Garçon, Pierre; Rivière, Jacques G.; Lagier, Jean-Christophe; Gentile, Stéphanie; Rosen, Lindsey; Shaw, Elana; Morio, Tomohiro; Tanaka, Junko; Dalmau, David; Tharaux, Pierre-Louis; Sene, Damien; Stepanian, Alain; Mégarbane, Bruno; Triantafyllia, Vasiliki; Fekkar, Arnaud; Heath, James; Franco, Jose; Anaya, Juan-Manuel; Solé-Violán, Jordi; Imberti, Luisa; Biondi, Andrea; Bonfanti, Paolo; Castagnoli, Riccardo; Delmonte, Ottavia; Zhang, Yu; Snow, Andrew; Holland, Steve; Biggs, Catherine; Moncada-Vélez, Marcela; Arias, Andrés; Lorenzo, Lazaro; Boucherit, Soraya; Anglicheau, Dany; Planas, Anna; Haerynck, Filomeen; Duvlis, Sotirija; Nussbaum, Robert; Ozcelik, Tayfun; Keles, Sevgi; Bousfiha, Aziz; El Bakkouri, Jalila; Ramirez-Santana, Carolina; Paul, Stéphane; Pan-Hammarstrom, Qiang; Hammarstrom, Lennart; Dupont, Annabelle; Kurolap, Alina; Metz, Christine; Aiuti, Alessandro; Casari, Giorgio; Lampasona, Vito; Ciceri, Fabio; Barreiros, Lucila; Dominguez-Garrido, Elena; Vidigal, Mateus; Zatz, Mayana; van de Beek, Diederik; Sahanic, Sabina; Tancevski, Ivan; Stepanovskyy, Yurii; Boyarchuk, Oksana; Nukui, Yoko; Tsumura, Miyuki; Vidaur, Loreto; Tangye, Stuart; Burrel, Sonia; Duffy, Darragh; Quintana-Murci, Lluis; Klocperk, Adam; Kann, Nelli; Shcherbina, Anna; Lau, Yu-Lung; Leung, Daniel; Coulongeat, Matthieu; Marlet, Julien; Koning, Rutger; Reyes, Luis; Chauvineau-Grenier, Angélique; Venet, Fabienne; monneret, guillaume; Nussenzweig, Michel; Arrestier, Romain; Boudhabhay, Idris; Baris-Feldman, Hagit; Hagin, David; Wauters, Joost; Meyts, Isabelle; Dyer, Adam; Kennelly, Sean; Bourke, Nollaig; Halwani, Rabih; Sharif-Askari, Fatemeh; Dorgham, Karim; Sallette, Jérôme; Mehlal-Sedkaoui, Souad; AlKhater, Suzan; Rigo-Bonnin, Raúl; Morandeira, Francisco; Roussel, Lucie; Vinh, Donald; Erikstrup, Christian; Condino-Neto, Antonio; Prando, Carolina; Bondarenko, Anastasiia; Spaan, András; Gilardin, Laurent; Fellay, Jacques; Lyonnet, Stanislas; Bilguvar, Kaya; Lifton, Richard; Mane, Shrikant; Anderson, Mark; Boisson, Bertrand; Béziat, Vivien; Zhang, Shen-Ying; Andreakos, Evangelos; Hermine, Olivier; Pujol, Aurora; Peterson, Pärt; Mogensen, Trine Hyrup; Rowen, Lee; Mond, James; Debette, Stéphanie; deLamballerie, Xavier; Burdet, Charles; Bouadma, Lila; Zins, Marie; Soler-Palacin, Pere; Colobran, Roger; Gorochov, Guy; Solanich, Xavier; Susen, Sophie; Martinez-Picado, Javier; Raoult, Didier; Vasse, Marc; Gregersen, Peter; Rodríguez-Gallego, Carlos; Piemonti, Lorenzo; Notarangelo, Luigi; Su, Helen; Kisand, Kai; Okada, Satoshi; Puel, Anne; Jouanguy, Emmanuelle; Rice, Charles; Tiberghien, Pierre; Zhang, Qian; Casanova, Jean-Laurent; Abel, Laurent; Cobat, Aurélie
title: The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies
date: 2022-01-14
journal: Res Sq
DOI: 10.21203/rs.3.rs-1225906/v1
sha: e23750dec40db16a3013fd3842fd5fcb88301129
doc_id: 757743
cord_uid: 00leff27

SARS-CoV-2 infection fatality rate (IFR) doubles with every five years of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ~20% of deceased patients across age groups. In the general population, they are found in ~1 % of individuals aged 20–70 years and in >4% of those >70 years old. With a sample of 1,261 deceased patients and 34,159 uninfected individuals, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to non-carriers. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRD was 17.0[95% CI:11.7–24.7] for individuals under 70 years old and 5.8[4.5–7.4] for individuals aged 70 and over, whereas, for autoantibodies neutralizing both molecules, the RRD was 188.3[44.8–774.4] and 7.2[5.0–10.3], respectively. IFRs increased with age, from 0.17%[0.12–0.31] for individuals <40 years old to 26.7%[20.3–35.2] for those ≥80 years old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84%[0.31–8.28] to 40.5%[27.82–61.20] for the same two age groups, for autoantibodies neutralizing both molecules. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, particularly those neutralizing both IFN-α2 and -ω. Remarkably, IFR increases with age, whereas RRD decreases with age. Autoimmunity to type I IFNs appears to be second only to age among common predictors of COVID-19 death.

There have already been more than 250 million SARS-CoV-2 infections and at least ve million deaths from COVID-19 worldwide. Interindividual clinical variability in the course of infection with SARS-CoV-2 is immense, ranging from silent infection in about 40% of cases to acute respiratory distress syndrome iñ 3% of cases [1] [2] [3] . Death occurs in ~1% of cases 4 . Age is the strongest epidemiological predictor of COVID-19 death, with the risk of death doubling every ve years of age from childhood onward 4, 5 . Men are also at greater risk of death than women 3, 6 . The COVID Human Genetic Effort 7 has shown that type I interferon (IFN) immunity is essential for protective immunity to respiratory infection with SARS-CoV-2 [8] [9] [10] [11] . We have reported that inborn errors of Toll-like receptor 3 (TLR3)-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in a small subset of patients 11 . Biochemically deleterious mutations of eight genes were found in 23 patients with critical COVID-19 (3.5% of 659 patients), including 18 patients under 60 years old. Remarkably, four patients, aged 25 to 50 years, had autosomal recessive (AR) de ciency of IFNAR1 or IRF7. Two other patients with AR IFNAR1 or TBK1 de ciency were independently reported 12, 13 . The penetrance of those defects is unknown, but it is probably higher for AR than for autosomal dominant disorders. We then reported that X-linked recessive TLR7 de ciency accounted for 1.8% of cases of life-threatening COVID-19 in men under 60 years old 10, 14 . The penetrance of this disorder is apparently high but incomplete, especially in children. De ciencies of IFNAR1 and IRF7 blunt type I IFN immunity across cell types, whereas defects of the TLR3 and TLR7 pathway preferentially affect respiratory epithelial cells and plasmacytoid dendritic cells, respectively 10, 15 .

We have also reported the presence of autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, with plasma diluted 1/10) of IFN-α2 and/or IFN-ω in about 10% of patients with critical COVID-19 pneumonia but not in individuals with asymptomatic or mild infection 9 . This nding has already been replicated in 13 other cohorts [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . We then detected auto-Abs neutralizing lower, more physiological concentrations (100 pg/mL, with plasma diluted 1/10) of IFN-α2 and/or IFN-ω in 13.6% of patients with life-threatening COVID-19, and 18% of deceased patients 8 . The proportion of male patients was greater in patients with auto-Abs than in patients without auto-Abs 8, 9 . In addition, 1.3% of patients with critical COVID-19 had auto-Abs neutralizing IFN-β (10 ng/mL, with plasma diluted 1/10), most without auto-Abs neutralizing IFN-α2 or IFN-ω. The prevalence of auto-Abs neutralizing IFN-α2 and/or IFN-ω in the general population increased with age, from 0.18% for 10 ng/mL and 1% for 100 pg/mL in individuals between 18 and 69 years old to 3.4% for 10 ng/mL and 6.3% for 100 pg/mL for individuals over 80 years old 8 . The prevalence of auto-Abs against IFN-β did not increase with age. The crude odds ratios (ORs) for critical COVID-19 as opposed to asymptomatic or mild infection in auto-Ab carriers relative to non-carriers ranged from 3 to 67, depending on the type I IFNs recognized and the concentrations neutralized 8 . At least 12 lines of evidence strongly suggest that auto-Abs against type I IFNs are strong determinants of COVID-19 death ( Table 1 ). The speci c impact of these auto-Abs on COVID-19 mortality according to age and sex remains unknown and is of major interest, as both the prevalence of these auto-Abs and the risk of death increase with age and are higher in men. Here, we estimated the relative risk of COVID-19 death (RRD) and the SARS-CoV-2 infection fatality rate (IFR) for type I IFN auto-Ab carriers relative to non-carriers, by sex and age category.

We enrolled 1,261 patients aged 20 to 99 years old who died from COVID-19 pneumonia, and 34,159 controls from the adult general population from whom samples were collected before the COVID-19 pandemic, as previously described 8 . All subjects were recruited according to protocols approved by local institutional review boards (IRBs). Auto-Ab determinations were performed as described by Bastard et al. 8, 46 , and were classi ed as neutralizing high concentrations (10 ng/ml) of IFN-α2, -ω, or -β, or low concentrations (100 pg/ml) of IFN-α2, or -ω (Additional Methods).

We estimated the RRD in individuals carrying auto-Abs neutralizing type I IFNs relative to non-carriers, using large samples of patients who died from COVID-19 and of individuals from the general population.

For each combination of auto-Abs, a Firth's bias-corrected logistic regression model, including auto-Ab status, sex and age was tted (Supplementary Table 1 ). For assessments of the effect of age and sex on the RRD due to auto-Abs, we added auto-Abs*sex and auto-Abs*age interaction terms to the Firth's logistic regression model (Additional Methods). We estimated the IFR for carriers of neutralizing auto-Abs infected with SARS-CoV-2 (IFR AAB ) following Bayes' theorem, and using the age-dependent prevalence of auto-Abs in deceased patients and in the general population together with the reported age-speci c IFR 4 as detailed in Additional Methods.

We estimated the RRD of individuals carrying auto-Abs neutralizing type I IFNs relative to non-carriers by Firth's logistic regression, using large samples of 1,261 patients who died from COVID-19 and 34,159 individuals from the general population from whom samples were collected before the pandemic. In this study design, in which controls are sampled from the baseline population regardless of disease status, the ORs obtained by logistic regression approximate to the RR in the absence of the assumption of rare disease 47 (see Additional Methods). For auto-Abs neutralizing low concentrations (100 pg/mL) of IFN-α2 and/or IFN-ω, we used 1,121 patients who died from COVID-19, and 10,778 individuals from the general population ( Table 2) .

Assessments of auto-Abs neutralizing high concentrations (10 ng/mL) of IFN-α2 and/or IFN-ω were available for 1,094 deceased patients, and 34,159 individuals from the general population (Table 2) . We also had assessments of auto-Abs neutralizing 10 ng/mL IFN-β for a subsample of 636 deceased patients and 9,126 individuals from the general population (Table 2 ). RRD was estimated by means of Firth's bias-corrected logistic regression, considering death as a binary outcome and adjusting for sex and age in six classes (20-39, 40-49, 50-59, 60-69, 70-79, ≥80 years). For assessment of the effect of age and sex on RRD, we added auto-Abs*age and auto-Abs*sex interaction terms to the logistic model (see Methods and Additional Methods).

We rst estimated the RRD for individuals carrying auto-Abs neutralizing low concentrations of IFN-α2 or IFN-ω. As expected, increasing age and maleness were highly signi cantly associated with greater risk of COVID-19 death (P values ≤10 -16 , Supplementary Table 1 ). Different age classes were used to test the interaction with the presence of auto-Abs, and the best t was obtained with a two-age class model (20- 69 and ≥70 years, Supplementary Table 2 ) with a signi cant effect of the auto-Abs*age interaction term (P value = 4×10 -6 ). The RRD associated with auto-Abs did not vary signi cantly with sex (P value = 0.81). These interaction results are fully consistent with the distribution of RRD according to age (Fig. 1A) and sex ( Fig. 1B) , with a clear decrease in RRD after the age of 70 years, and no sex effect. Overall, the RRD for individuals carrying auto-Abs neutralizing IFN-α2 or IFN-ω decreased from 17.0 [95% CI: 11.7-24.7] before the age of 70 years to 5.8 [4.5-7.4 ] for individuals ≥70 years old ( Fig. 2A, Supplementary Table 3 ).

We then applied the same strategy to other combinations of auto-Abs neutralizing low concentrations of IFN, and observed similar age effects on RRDs (Supplementary Table 1 

In this study, we estimated RR from the general population 47 to obtain the RRDs associated with auto-Abs. We also used IFR values previously reported for the general population 4 to estimate IFR AAB. We report high RRDs for carriers of auto-Abs neutralizing type I IFNs, ranging from 2.6 for auto-Abs neutralizing IFN-β (high concentration) in subjects over 70 years old to >150 for auto-Abs neutralizing both IFN-α2 and IFN-ω in subjects under 70 years old. For all types of auto-Abs, RRDs were three to 26 times higher in subjects under 70 years old than in older individuals. This is consistent with the increasing prevalence of auto-Abs in the general population with age (~1% under 70 years of age and >4% over 70 years of age), whereas the proportion of deceased patients with these auto-Abs is stable across age categories (~15-20%). The lower RRD observed in the elderly may be partly explained epidemiologically, by the larger contribution of other mortality risk factors, such as comorbid conditions, which become more frequent with increasing age. At the cellular level, aging is associated with immunosenescence, which may contribute to a defective innate and adaptive response to SARS-CoV-2 infection, thereby conferring a predisposition to severe COVID-19 48 . At the molecular level, global type I

has been shown to decline with age [49] [50] [51] [52] . These epidemiological, cellular, and molecular factors probably overlap. Thus, despite their increasing prevalence with age, auto-Abs against type I IFNs make a decreasing contribution to the risk of COVID-19 death with age due to the progressive development of additional age-dependent risk factors, including other mechanisms of type I IFN de ciency. However, for the very same reasons, IFR AAB increases dramatically with age in patients with auto-Abs, reaching 68.7%

for carriers of auto-Abs neutralizing high concentrations of both IFN-α2 and -ω.

RRD and IFR AAB varied considerably with the IFNs recognized and the concentrations neutralized by auto-Abs. For most combinations involving auto-Abs against IFN-α2 and/or -ω, the neutralization of low concentrations was associated with a lower RRD and a lower IFR AAB than the neutralization of high concentrations, suggesting that residual type I IFN activity may be bene cial in at least some patients.

Blood IFN-α concentrations during acute asymptomatic or paucisymptomatic SARS-CoV-2 infection typically range from 1 to 100 pg/mL 8 . In addition, the presence of auto-Abs neutralizing both IFN-α2 and IFN-ω was associated with the highest RRD and IFR AAB values. Interestingly, IFN-α2 and IFN-ω are encoded by two genes, IFNA2 and IFNW1, that have been shown to have evolved under strong selective constraints 53 , consistent with their neutralization being harmful to the host. In addition, patients with auto-Abs against IFN-α2 have been shown to neutralize all 13 IFN-α subtypes 8, 9 , rendering any potential IFN-α redundancy inoperative 8, 9 . Accordingly, the IFR AAB values for carriers of auto-Abs against IFN-α2

were higher than those for carriers of auto-Abs against IFN-ω in subjects under 60 years of age. In older age groups, this difference tended to disappear, consistent with the lower impact of auto-Abs in the elderly, as discussed above. Finally, auto-Abs neutralizing IFN-β were less common, and associated with lower RRD and IFR AAB values (by about one order of magnitude) than auto-Abs against IFN-α2 and/or IFN-ω, in all age groups except the over-80s. This less deleterious effect of auto-Abs neutralizing IFN-β is consistent with a mouse study showing that the blockade of IFN-β alone does not alter the early dissemination of lymphocytic choriomeningitis virus 54 . Overall, auto-Abs against type I IFNs are associated with very high RRD and IFR values, and the magnitude of this effect is much larger than that of other known common risk factors apart from age, such as maleness (Fig. 4) , comorbidities, or the most signi cant common genetic variant on chromosome 3, all of which have been associated to lifethreatening COVID-19 with ORs of about 2 3 .

Despite the lower prevalence of these auto-Abs in younger than in older individuals, the much higher IFR AAB observed in individuals with these auto-Abs suggests that the testing of infected individuals in all age groups is warranted. Particular attention should be paid to patients, especially children, with known autoimmune or genetic conditions associated with the production of auto-Abs against type I IFNs. Early treatments could be provided 55 , including monoclonal antibodies 56 , new antiviral drugs, and/or IFN-β in the absence of auto-Abs against IFN-β 57,58 . Rescue treatment by plasma exchange is a therapeutic option in patients who already have pneumonia 30 . A screening of uninfected elderly people could be considered,

given that these auto-Abs are found in 4% of individuals over 70 years old. Carriers of auto-Abs should be vaccinated against SARS-CoV-2 as a priority, and should bene t from a booster, whatever their age, and ideally from a monitoring of their antibody response to the vaccine. They should not receive liveattenuated vaccines, including the yellow fever vaccine (YFV-17D) and anti-SARS-CoV-2 vaccines based on the YFV-17D backbone 46 . In cases of SARS-CoV-2 infection, vaccinated patients should be closely monitored. As SARS-CoV-2 vaccination coverage increases and mortality due to COVID-19 decreases over time, it will be important to re-evaluate the risk of fatal COVID-19 in vaccinated individuals with and without auto-Abs. It is currently unclear whether these auto-Abs impair antibody responses to vaccines, and whether a vaccine-triggered antibody response can overcome type I IFN de ciency in response to large or even medium-sized viral inocula. Finally, further investigations are required to determine the contribution of these auto-Abs to other severe viral diseases, and to elucidate the mechanisms underlying their development, which may be age-dependent. In the meantime, auto-Abs against type I IFNs should be considered as a leading common predictor of life-threatening COVID-19 after age, as their detection has a much greater predictive value for death, and, by inference, hospitalization and critical COVID-19, than sex, comorbidities, and common genetic variants (Fig. 3 ).

Tables In patients for whom a sample collected before the COVID-19 pandemic was available, the auto-Abs were found to pre-exist infection 30 These auto-Abs are found in the uninfected general population, and their prevalence increases after the age of 65 years 8 Auto-Abs are associated with COVID-19 severity Patients with inborn errors underlying these auto-Abs from infancy onward (e.g. APS-1) have a very high risk of developing critical COVID-19 pneumonia 30 The population of patients with critical disease includes a higher proportion of individuals producing these auto-Abs than the population of patients with silent or mild infection (ORs depending on the nature, number, and concentrations of type I IFN neutralized) 8 The results concerning the proportions of critical cases with auto-Abs against type I IFNs have already been replicated in >15 different cities (Americas, Europe, Asia) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Auto-Abs against type I IFNs neutralize host antiviral activity These auto-Abs neutralize the antiviral activity of type I IFNs against SARS-CoV-2 in vitro 9 These auto-Abs are found in vivo in the blood of SARS-CoV-2-infected patients, where they neutralize type I IFN 31 These auto-Abs are found in vivo in the respiratory tract of patients, where they neutralize type I IFN [32] [33] [34] A key virulence factor of SARS-CoV-2 in vitro is its capacity to impair type I IFN immunity 35 Animals with type I IFN deficiency develop critical disease, including animals treated with mAbs that neutralize type I IFNs 36 Auto-Abs against cytokines are clinical phenocopies of the corresponding inborn errors Patients with auto-Abs against type I IFNs are phenocopies of IFNAR1 -/-, IFNAR2 -/-, and IRF7 -/patients with critical COVID-19 pneumonia 11 Patients with auto-Abs against IL-6, IL-17, GM-CSF, and type II IFN are phenocopies of the corresponding inborn errors and underlie staphylococcal disease, mucocutaneous candidiasis, nocardiosis, and mycobacterial diseases, respectively [37] [38] [39] [40] [41] [42] [43] [44] [45] Table 2 . Characteristics of the general population cohort and of the cohort of patients who died from COVID-19, by age, sex and autoantibody status Figure 1 Relative risks of death associated with auto-Abs neutralizing low concentrations of IFN-α2 or -ω, by age and sex. RRDs for individuals with auto-Abs neutralizing low concentrations of IFN-α2 or IFN-ω relative to individuals without such auto-Abs, by age and sex. RRDs are displayed on a logarithmic scale (A) for six age classes, and (B) for male and female subjects under and over the age of 70 years. Vertical bars represent the 95% CI. SARS-CoV-2 infection fatality rates by age. IFRs are provided in the general population for both sexes (gray) and for males only (blue) using the data of O'Driscoll et al. 4 ; IFR AAB (green) are shown for individuals carriers of auto-Abs neutralizing low concentrations of IFN-α2 or IFN-ω. Auto-Abs against type I IFNs are associated with high RRDs and strongly increase IFR, to a much greater extent than maleness, and by inference than other classical common risk factors providing ORs of death similar to maleness (around 2) such as some comorbidities, or the most signi cant common genetic variant on chromosome 3 3 .

Characteristics of SARS-CoV-2 and COVID-19

Burden and characteristics of COVID-19 in the United States during 2020

Life-Threatening COVID-19: Defective Interferons Unleash Excessive In ammation

Age-speci c mortality and immunity patterns of SARS-CoV-2

Assessing the age speci city of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications

Immune determinants of COVID-19 disease presentation and severity

A Global Effort to De ne the Human Genetics of Protective Immunity to SARS-CoV-2 Infection

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

X-linked recessive TLR7 de ciency in ~1% of men under 60 years old with lifethreatening COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

A Case of Autosomal Recessive Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) De ciency with Severe COVID-19

TBK1 and TNFRSF13B mutations and an autoin ammatory disease in a child with lethal COVID-19

X-Linked TLR7 De ciency Underlies Critical COVID-19 Pneumonia in a Male Patient with Ataxia-Telangiectasia

Mechanisms of viral in ammation and disease in humans

Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma

Diverse functional autoantibodies in patients with COVID-19

Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona

Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19

New-onset IgG autoantibodies in hospitalized patients with COVID-19

Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19

COVID-19 convalescent plasma composition and immunological effects in severe patients

Identi cation of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and u comparison

The interferon landscape along the respiratory tract impacts the severity of COVID-19

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Mouse model of SARS-CoV-2 reveals in ammatory role of type I interferon signaling

Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-speci c autoimmunity

Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans

Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma

Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6

Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

Autoantibodies against cytokines: phenocopies of primary immunode ciencies?

Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines

Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis

Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories

Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine

Empirical evaluation of the in uence of control selection schemes on relative risk estimation: the Welsh nickel workers study

SARS-CoV-2, COVID-19 and the Ageing Immune System

Plasmacytoid dendritic cell and myeloid dendritic cell function in ageing: A comparison between elderly and young adult women

COVID-19 and the human innate immune system

The JAK-STAT pathway at twenty

Natural mucosal barriers and COVID-19 in children

Evolutionary genetic dissection of human interferons

Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-beta

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Interferon-beta Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2

Safety and e cacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Neutralization 100 pg/mL Neutralization 10 ng/mL population cohort (controls) and age at death for COVID-19 patients. b IFN-β neutralization experiments were

5% male, mean age 60.6 years) from the general population and 636 COVID-19 patients (71.1% male

We thank the patients and their families for placing their trust in us. We thank the members of both Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM; and the University of Paris. P.B. was supported by the FRM (EA20170638020). P.B., J.R., and

This is a list of supplementary les associated with this preprint. Click to download.